ECSP066534A - DOSAGE FORMS OF CONTROLLED OXYCODONE, ORALS, ONCE A DAY - Google Patents
DOSAGE FORMS OF CONTROLLED OXYCODONE, ORALS, ONCE A DAYInfo
- Publication number
- ECSP066534A ECSP066534A EC2006006534A ECSP066534A ECSP066534A EC SP066534 A ECSP066534 A EC SP066534A EC 2006006534 A EC2006006534 A EC 2006006534A EC SP066534 A ECSP066534 A EC SP066534A EC SP066534 A ECSP066534 A EC SP066534A
- Authority
- EC
- Ecuador
- Prior art keywords
- profiles
- dosage forms
- orals
- vivo
- day
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
Se proveen formulaciones de oxicodona que producen perfiles de plasma en estado estable in vivo sustancialmente planos; los niveles de tolerancia relacionados con dichos perfiles y niveles de tolerancia relacionados con perfiles bifásicos no se muestran estadísticamente diferentes; los perfiles de plasma en estado estable in vivo sustancialmente planos se producen a través de formas de dosificación que tienen perfiles de liberación in vitro sustancialmente de orden cero; dichos perfiles de liberación producen bajos niveles de Cmax in vivo de dosis única los cuales pueden reducir la probabilidad de efectos secundarios adversos.Oxycodone formulations that produce substantially flat stable in vivo plasma profiles are provided; the tolerance levels related to said profiles and tolerance levels related to biphasic profiles are not statistically different; substantially flat in vivo stable plasma profiles are produced through dosage forms having substantially zero-order in vitro release profiles; such release profiles produce low levels of Cmax in vivo single dose which can reduce the likelihood of adverse side effects.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51588003P | 2003-10-29 | 2003-10-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP066534A true ECSP066534A (en) | 2006-11-24 |
Family
ID=34549453
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2006006534A ECSP066534A (en) | 2003-10-29 | 2006-04-28 | DOSAGE FORMS OF CONTROLLED OXYCODONE, ORALS, ONCE A DAY |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP1677798A2 (en) |
JP (1) | JP2007509979A (en) |
KR (1) | KR20060108690A (en) |
CN (1) | CN1933837A (en) |
AU (1) | AU2004285547A1 (en) |
BR (1) | BRPI0415639A (en) |
CA (1) | CA2546691A1 (en) |
EC (1) | ECSP066534A (en) |
IL (1) | IL175193A0 (en) |
MA (1) | MA28215A1 (en) |
NO (1) | NO20062398L (en) |
RU (1) | RU2006118323A (en) |
WO (1) | WO2005041968A2 (en) |
ZA (1) | ZA200604310B (en) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE526950T1 (en) | 1999-10-29 | 2011-10-15 | Euro Celtique Sa | CONTROLLED RELEASE HYDROCODONE FORMULATIONS |
US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
WO2002036099A1 (en) | 2000-10-30 | 2002-05-10 | Euro-Celtique S.A. | Controlled release hydrocodone formulations |
UA81224C2 (en) * | 2001-05-02 | 2007-12-25 | Euro Celtic S A | Dosage form of oxycodone and use thereof |
US20110104214A1 (en) | 2004-04-15 | 2011-05-05 | Purdue Pharma L.P. | Once-a-day oxycodone formulations |
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
US8075872B2 (en) | 2003-08-06 | 2011-12-13 | Gruenenthal Gmbh | Abuse-proofed dosage form |
DE10336400A1 (en) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Anti-abuse dosage form |
DE10361596A1 (en) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Process for producing an anti-abuse dosage form |
US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
DE102005005446A1 (en) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Break-resistant dosage forms with sustained release |
DE102004032051A1 (en) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Process for the preparation of a secured against misuse, solid dosage form |
DE102004032049A1 (en) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Anti-abuse, oral dosage form |
DE102005005449A1 (en) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Process for producing an anti-abuse dosage form |
SA07280459B1 (en) | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic |
DE102007011485A1 (en) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Dosage form with more difficult abuse |
JP5774853B2 (en) | 2008-01-25 | 2015-09-09 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Pharmaceutical dosage form |
US9226907B2 (en) | 2008-02-01 | 2016-01-05 | Abbvie Inc. | Extended release hydrocodone acetaminophen and related methods and uses thereof |
CA2723438C (en) | 2008-05-09 | 2016-10-11 | Gruenenthal Gmbh | Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step |
MX2012000317A (en) | 2009-07-22 | 2012-02-08 | Gruenenthal Gmbh | Hot-melt extruded controlled release dosage form. |
MX2012000369A (en) | 2009-07-22 | 2012-02-01 | Gruenenthal Gmbh | Tamper-resistant dosage form for oxidation-sensitive oploids. |
US20110150989A1 (en) * | 2009-12-22 | 2011-06-23 | Mallinkckrodt Inc. | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans |
EP2555756B1 (en) * | 2010-04-07 | 2018-08-22 | Lupin Limited | Controlled release pharmaceutical compositions of tapentadol |
RU2604676C2 (en) | 2010-09-02 | 2016-12-10 | Грюненталь Гмбх | Destruction-resistant dosage form containing an inorganic salt |
ES2487244T3 (en) | 2010-09-02 | 2014-08-20 | Grünenthal GmbH | Handling resistant dosage form comprising an anionic polymer |
PT2736495T (en) | 2011-07-29 | 2017-11-30 | Gruenenthal Gmbh | Tamper-resistant tablet providing immediate drug release |
US20130028972A1 (en) | 2011-07-29 | 2013-01-31 | Grunenthal Gmbh | Tamper-resistant tablet providing immediate drug release |
BR112014019988A8 (en) | 2012-02-28 | 2017-07-11 | Gruenenthal Gmbh | BREAK-RESISTANT DOSAGE FORM COMPRISING A PHARMACOLOGICALLY ACTIVE COMPOUND AND AN ANIONIC POLYMER |
JP6282261B2 (en) | 2012-04-18 | 2018-02-21 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Unauthorized use and overdose prevention pharmaceutical dosage forms |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
BR112015029616A2 (en) | 2013-05-29 | 2017-07-25 | Gruenenthal Gmbh | tamper-resistant dosage form with bimodal release profile |
CA2907950A1 (en) | 2013-05-29 | 2014-12-04 | Grunenthal Gmbh | Tamper-resistant dosage form containing one or more particles |
KR20160031526A (en) | 2013-07-12 | 2016-03-22 | 그뤼넨탈 게엠베하 | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
MX371372B (en) | 2013-11-26 | 2020-01-28 | Gruenenthal Gmbh | Preparation of a powdery pharmaceutical composition by means of cryo-milling. |
CA2947786A1 (en) | 2014-05-12 | 2015-11-19 | Grunenthal Gmbh | Tamper resistant immediate release capsule formulation comprising tapentadol |
WO2015181059A1 (en) | 2014-05-26 | 2015-12-03 | Grünenthal GmbH | Multiparticles safeguarded against ethanolic dose-dumping |
CN107889459A (en) | 2015-04-24 | 2018-04-06 | 格吕伦塔尔有限公司 | Tamper resistant dosage form with release immediately and to solvent-extracted resistance |
AU2016319203A1 (en) | 2015-09-10 | 2018-02-22 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
TW202329972A (en) | 2016-08-10 | 2023-08-01 | 瑞士商赫孚孟拉羅股份公司 | Pharmaceutical compositions comprising akt protein kinase inhibitors |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5914131A (en) * | 1994-07-07 | 1999-06-22 | Alza Corporation | Hydromorphone therapy |
UA81224C2 (en) * | 2001-05-02 | 2007-12-25 | Euro Celtic S A | Dosage form of oxycodone and use thereof |
US20040010000A1 (en) * | 2002-04-29 | 2004-01-15 | Ayer Atul D. | Methods and dosage forms for controlled delivery of oxycodone |
MXPA04012021A (en) * | 2002-05-31 | 2005-08-16 | Johnson & Johnson | Dosage forms and compositions for osmotic delivery of variable dosages of oxycodone. |
-
2004
- 2004-10-28 CN CNA2004800394188A patent/CN1933837A/en active Pending
- 2004-10-28 RU RU2006118323/15A patent/RU2006118323A/en unknown
- 2004-10-28 KR KR1020067010336A patent/KR20060108690A/en not_active Application Discontinuation
- 2004-10-28 JP JP2006538357A patent/JP2007509979A/en not_active Withdrawn
- 2004-10-28 EP EP04817492A patent/EP1677798A2/en not_active Withdrawn
- 2004-10-28 WO PCT/US2004/036132 patent/WO2005041968A2/en active Application Filing
- 2004-10-28 BR BRPI0415639-0A patent/BRPI0415639A/en not_active IP Right Cessation
- 2004-10-28 AU AU2004285547A patent/AU2004285547A1/en not_active Abandoned
- 2004-10-28 CA CA002546691A patent/CA2546691A1/en not_active Abandoned
-
2006
- 2006-04-25 IL IL175193A patent/IL175193A0/en unknown
- 2006-04-28 MA MA28979A patent/MA28215A1/en unknown
- 2006-04-28 EC EC2006006534A patent/ECSP066534A/en unknown
- 2006-05-26 NO NO20062398A patent/NO20062398L/en not_active Application Discontinuation
- 2006-05-26 ZA ZA200604310A patent/ZA200604310B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2546691A1 (en) | 2005-05-12 |
WO2005041968A2 (en) | 2005-05-12 |
RU2006118323A (en) | 2007-12-10 |
AU2004285547A1 (en) | 2005-05-12 |
CN1933837A (en) | 2007-03-21 |
KR20060108690A (en) | 2006-10-18 |
ZA200604310B (en) | 2007-11-28 |
JP2007509979A (en) | 2007-04-19 |
MA28215A1 (en) | 2006-10-02 |
EP1677798A2 (en) | 2006-07-12 |
NO20062398L (en) | 2006-07-27 |
IL175193A0 (en) | 2008-04-13 |
WO2005041968A3 (en) | 2006-06-22 |
BRPI0415639A (en) | 2006-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP066534A (en) | DOSAGE FORMS OF CONTROLLED OXYCODONE, ORALS, ONCE A DAY | |
CR7500A (en) | DOSAGE FORMS OF AZITROMICIDE WITH REDUCED SIDE EFFECTS | |
UY28941A1 (en) | REPLACED INDAZOLS, COMPOSITIONS THAT CONTAIN THEM, PREPARATION PROCEDURE AND ITS USE | |
BR0309620A (en) | Methods and dosage forms for controlled release of oxycodone | |
NO20062504L (en) | Compositions and dosage forms for improved absorption | |
CR9262A (en) | FORMULATIONS IN TABLET OF CCI-1179 ORALY AVAILABLE | |
CA2683786C (en) | Use of tapentadol in the treatment of pain and with a reduced incidence of tapentadol-induced side-effects | |
TW200716157A (en) | Pharmaceutical formulations and methods of treatment using the same | |
BRPI0707612B8 (en) | sealed vessel and liquid formulations contained therein | |
SV2003001493A (en) | SUBSTITUTED INDAZOLS, COMPOSITIONS THAT CONTAIN THEM, MANUFACTURING AND USE PROCEDURE | |
WO2007016563A3 (en) | Alcohol resistant pharmaceutical formulations | |
TW200640497A (en) | Pharmaceutical formulations and methods of use | |
AR054595A1 (en) | GUANFACINE PHARMACEUTICAL FORMULATIONS / COMPOSITIONS APPROPRIATE FOR DAILY ADMINISTRATION FORM IN A SINGLE DOSE | |
PA8559501A1 (en) | PHARMACEUTICAL FORMULATIONS OF 5,7,14-TRIAZATETRACICLO [10.3.1.02,11.04,9] -HEXADECA-2 (11), 3,5,7,9-PENTAENO | |
PA8616201A1 (en) | PHARMACEUTICAL COMPOSITIONS OF SUSTAINED LIBERATION | |
AR047191A1 (en) | METHODS OF TREATMENT OF HEPATIC FIBROSIS | |
ATE505203T1 (en) | PHARMACEUTICAL COMBINATION OF ALISKIREN AND VALSARTAN | |
TW200509992A (en) | Dosage form containing pantoprazole as active ingredient | |
EA200970353A1 (en) | COMBINED MEDICINE | |
TW200503785A (en) | Dosage form containing (S)-pantoprazole as active ingredient | |
ATE460934T1 (en) | PHARMACEUTICAL PREPARATIONS OF CIPROFLOXACIN | |
DK1220676T3 (en) | Prevention of colorectal cancer | |
MX2009008813A (en) | Pharmaceutical composition containing phloroglucinol and paracetamol. | |
EA201290378A1 (en) | COMPOSITIONS CONTAINING NESTEROIDIC ANTI-INFLAMMATORY MEDICINES | |
PL378106A1 (en) | Method for producing a pharmaceutical composition in the form of fibrate-containing tablets and tablets produced by said method |